天美传媒

Dr. Gauduin has more than 25 years of experience in HIV/AIDS research and medical microbiology. She has been working extensively on HIV and the development of novel vaccine strategies using the non-human primate model for AIDS. In her work, she uses epithelial stem cells and weakened recombinant papillomavirus as vaccine- vectors to protect against multiple low-dose mucosal challenges. Dr. Gauduin is also developing a neonatal model for tuberculosis to study HIV/TB co-infection in pediatric AIDS. Her specific research interests are: Early events of simian immunodeficiency virus (SIV) transmission in a macaque model Host immune responses to infectious diseases Early virus-specific T cell responses in neonates Tuberculosis/SIV coinfection in pediatric AIDS

Dr. Lesley Fellows is a neurologist specializing in disorders of cognition. She has a particular interest in the functions of the brain's frontal lobes. Her research program focuses on the brain basis of decision making in humans, using the tools of cognitive neuroscience. She studies how focal brain damage or neurochemical dysfunction affects all aspects of decision making, how options are generated and organized, how they are valued and compared, and how choices are made. She is also interested in more general questions about the roles of the frontal lobes in the regulation of emotion, the expression of personality traits, and the representation of past and future information. This work has relevance for understanding impaired executive function following frontal lobe injury from aneurysm rupture, stroke, or tumor growth, as well as in degenerative conditions such as Parkinson鈥檚 Disease and some forms of dementia. It also provides insights into how the component processes that underlie decision making are carried out in the intact brain.

Cheryl Healton, DrPH, is dean of the College of Global Public Health and professor of public health policy and management at New York University.  A public health leader and scholar, Healton has published more than 100 peer-reviewed papers and special reports on topics including HIV/AIDS, the opioid crisis, public health education, health policy, substance abuse, and tobacco. 

Healton was the founding president and CEO of Legacy (now Truth Initiative), a national foundation dedicated to tobacco control created by the tobacco industry鈥檚 Master Settlement Agreement. Healton worked to further the foundation鈥檚 mission: to build a world where young people reject tobacco and anyone can quit. During her time with Legacy, Healton guided the national youth tobacco prevention counter-marketing campaign, truth庐, which has been credited with reducing youth smoking prevalence to near record lows. 

Healton is currently focused on what lessons can be learned from the tobacco industry鈥檚 Master Settlement Agreement and applied to other public health issues, including opioids, gun violence, obesity, and global warming. https://www.nejm.org/doi/10.1056/NEJMp1802633

Thomas N. Denny, MSc, M.Phil, is the Chief Operating Officer of the Duke Human Vaccine Institute (DHVI) and the Center for HIV/AIDS Vaccine Immunology (CHAVI), and a Professor of Medicine in the Department of Medicine at Duke University Medical Center. He is also an Affiliate Member of the Duke Global Health Institute. He has recently been appointed to the Duke University Fuqua School of Business Health Sector Advisory Council. Previously, he was an Associate Professor of Pathology, Laboratory Medicine and Pediatrics, Associate Professor of Preventive Medicine and Community Health and Assistant Dean for Research in Health Policy at the New Jersey Medical School, Newark, New Jersey. He has served on numerous committees for the NIH over the last two decades and currently is the principal investigator of an NIH portfolio in excess of 56 million dollars. Mr. Denny was a 2002-2003 Robert Wood Johnson Foundation Health Policy Fellow at the Institute of Medicine of the National Academies (IOM). As a fellow, he served on the US Senate Health, Education, Labor and Pensions Committee with legislation/policy responsibilities in global AIDS, bioterrorism, clinical trials/human subject protection and vaccine related-issues.

, is a professor of clinical medicine in the Department of Medicine, Division of Infectious Diseases at the University of California, San Diego. She sees patients in the Owen Clinic and the infectious diseases clinic. She also cares for people during hospital stays.
Dr. Torriani is medical director of the UC San Diego Infection Prevention and Clinical Epidemiology and the tuberculosis control units at UC San Diego Health. In collaboration with Atlas Public Health, she has been instrumental in creating an extensive electronic microbiology surveillance and pharmacy utilization program called Guardian that allows for internal data mining, surveillance, unit-specific antibiogram production, and external reporting of contagious infections to San Diego Public Health and to the California Department of Public Health (CDPH) of Healthcare Associated Infections (HAI).
Since 2010, Dr. Torriani has served on the Metrics Group for CA HAI Reporting, an independent group of experts discussing best standards and methods for HAI reporting in California. 
She is fluent in five languages: Italian, French, German, Spanish and English.